FTY720 enhances PP2A activity by disrupting the interaction between PP2A and SET, an endogenous PP2A inhibitor, and is prescribed for managing multiple sclerosis (Pelletier and Hafler, 2012). This evidence concerns the gene PTPA and multiple sclerosis.